Anna Purdum

Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States

Joshua A. Roth, Sean D. Sullivan, Vincent Lin et al. · Journal of Medical Economics · 2018 · 111 citations

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Marcelo C. Pasquini, Frederick L. Locke, Alex F. Herrera et al. · Blood · 2019 · 94 citations

Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies

Anna Purdum, Ryan Tieu, Sheila R. Reddy et al. · The Oncologist · 2019 · 39 citations · Full text

Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States

Veena Shankaran, Jesse D. Ortendahl, Anna Purdum et al. · American Journal of Clinical Oncology · 2015 · 38 citations

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Karl M. Kilgore, Iman Mohammadi, Amy Schroeder et al. · Blood · 2019 · 25 citations